Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With…(ARTISTRY-7) | Phase 3 | terminated | Oct 25, 2021 | Mural Oncology, Inc | Study terminated due to business and strategic decision. | Sponsor / business decision |
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 12, 2024 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | funding withdrawn | Funding |
| NCT04936230 | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | Phase 2 | terminated | Jun 23, 2021 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain… | Phase 2 | withdrawn | Jun 10, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT03485794 | Collection of Blood in Studying Metabolites in Patients With Prostate Cancer | — | terminated | Apr 2, 2018 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | Phase 2 / Phase 3 | terminated | Nov 12, 2019 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a… | Phase 2 | terminated | Apr 7, 2020 | University of Washington | Slow accrual | Enrollment / accrual |
| NCT05248789 | OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | Phase 2 | terminated | Feb 21, 2022 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT05369000 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant… | Phase 1 | terminated | May 11, 2022 | Lava Therapeutics | The trial was intended to be a Phase 1/2 trial (but the trial never moved forward to Phase 2). | Other (stated, no rule matched) |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer… | N/A | terminated | May 16, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT03432897 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects…(337) | Phase 2 | terminated | Feb 14, 2018 | Brown University | Lack of enrollment secondary to eligibility criteria | Enrollment / accrual |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT04688333 | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With… | — | withdrawn | Dec 30, 2020 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | Phase 1 / Phase 2 | terminated | Jan 24, 2019 | University of Oxford | COVID stopped all trials - and ADVANCE could not restart again after the pandemic | COVID-19 / pandemic |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | Phase 2 | terminated | Sep 25, 2019 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Phase 1 | terminated | Feb 5, 2021 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT05687721 | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | Phase 1 / Phase 2 | withdrawn | Jan 18, 2023 | VA Office of Research and Development | The study drug is not available. | Other (stated, no rule matched) |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent… | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02446860 | A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic…(ADAPTeR) | Phase 2 | terminated | May 18, 2015 | Royal Marsden NHS Foundation Trust | The study was unable to recruit the target number of patients (enrolled 15 instead of 19) and did… | Enrollment / accrual |
| NCT06421311 | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With…(URADJ) | — | terminated | May 20, 2024 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | Phase 1 | terminated | Sep 11, 2017 | Dana-Farber Cancer Institute | Expansion cohort was not open | Other (stated, no rule matched) |
| NCT03294694 | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | Phase 1 | terminated | Sep 27, 2017 | Dana-Farber Cancer Institute | Safety Implications | Safety / toxicity |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant… | Phase 1 / Phase 2 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | Abandoned | Other (stated, no rule matched) |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | Phase 1 | terminated | Jun 16, 2021 | Rahul Aggarwal | Slow accrual | Enrollment / accrual |
| NCT02756130 | Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade… | Phase 1 / Phase 2 | withdrawn | Apr 29, 2016 | Jonsson Comprehensive Cancer Center | funding was not secured | Funding |
| NCT03456700 | Auranofin and Sirolimus in Treating Participants With Ovarian Cancer | Phase 2 | terminated | Mar 7, 2018 | Mayo Clinic | The study is closed per results from the interim analysis. | Efficacy / futility |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With… | Phase 2 | terminated | Jan 5, 2022 | Coherus Oncology, Inc. | The study was terminated for strategic reasons, not due to any safety concerns. | Safety / toxicity |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or… | Phase 1 | terminated | Feb 16, 2022 | Kinnate Biopharma | Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor… | Enrollment / accrual |
| NCT02569957 | Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in… | Phase 2 | terminated | Oct 7, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | The trial was halted prematurely due to slow accrual. | Enrollment / accrual |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney… | Early Phase 1 | withdrawn | Feb 2, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated by the IRB | Other (stated, no rule matched) |
| NCT04483544 | Pembrolizumab and Olaparib in Cervical Cancer Patients | Phase 2 | terminated | Jul 23, 2020 | Baptist Health South Florida | Poor accrual related to change in standard of care treatment for this population. | Enrollment / accrual |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT02122172 | Afatinib in Advanced Refractory Urothelial Cancer | Phase 2 | terminated | Apr 24, 2014 | University of Chicago | Unable to meet accrual goal after several years | Enrollment / accrual |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in… | Phase 2 | withdrawn | Jul 10, 2018 | M.D. Anderson Cancer Center | Committee could not find that the regulatory approval are met to re-approve this study. | Other (stated, no rule matched) |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | Phase 1 | withdrawn | Jul 11, 2023 | Orion Biotechnology Polska Sp. z o.o. | study terminated due to changes in the drug development plan | Other (stated, no rule matched) |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With… | Phase 1 / Phase 2 | terminated | Sep 21, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05208229 | The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium -…(WB-LuPSMA) | — | terminated | Jan 26, 2022 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | The study was linked to another protocol that is over | Other (stated, no rule matched) |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen… | Phase 1 | withdrawn | Oct 23, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual | Enrollment / accrual |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | — | withdrawn | Jan 14, 2022 | WellSpan Health | study was not started at WellSpan | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 28, 2025source: clinicaltrials